Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference
Aclarion (Nasdaq: ACON) participated in the International Society of Pain and Neuroscience Annual Meeting in London on Oct 13, 2025, where a session co‑moderated by Doug Beall, M.D., highlighted the role of MR Spectroscopy and Aclarion’s Nociscan in identifying biomarkers of discogenic low back pain.
Nociscan is described as a SaaS platform that converts MR spectroscopy signals into objective biomarkers to help differentiate painful vs non‑painful lumbar discs and inform personalized treatment decisions. The company emphasized multidisciplinary clinical engagement and insurer approval at a UK clinic for study access.
Aclarion (Nasdaq: ACON) ha partecipato all'Annual Meeting della International Society of Pain and Neuroscience a Londra il 13 ottobre 2025, dove una sessione co‑presieduta da Doug Beall, M.D., ha evidenziato il ruolo della MR Spectroscopy e del Nociscan di Aclarion nell'identificazione di biomarcatori del dolore lombare discogenico.
Nociscan è descritto come una piattaforma SaaS che converte i segnali di MR spectroscopy in biomarcatori oggettivi per aiutare a differenziare i dischi lombari dolorosi da quelli non dolorosi e guidare decisioni di trattamento personalizzate. L'azienda ha sottolineato l'impegno clinico multidisciplinare e l'approvazione da parte degli assicuratori in una clinica del Regno Unito per l'accesso allo studio.
Aclarion (Nasdaq: ACON) participó en la Reunión Anual de la International Society of Pain and Neuroscience en Londres el 13 de octubre de 2025, donde una sesión co‑moderada por Doug Beall, M.D., destacó el papel de la MR Spectroscopy y el Nociscan de Aclarion para identificar biomarcadores del dolor lumbar discogénico.
Nociscan se describe como una plataforma SaaS que convierte las señales de MR spectroscopy en biomarcadores objetivos para ayudar a diferenciar discos lumbares dolorosos de los no dolorosos e informar decisiones de tratamiento personalizadas. La compañía enfatizó el compromiso clínico multidisciplinario y la aprobación de aseguradoras en una clínica del Reino Unido para el acceso al estudio.
Aclarion (Nasdaq: ACON)은 2025년 10월 13일 런던에서 열린 International Society of Pain and Neuroscience 연례 회의에 참석했으며, Doug Beall, M.D.가 공동 진행한 세션에서 MR 분광법의 역할과 Aclarion의 Nociscan이 디스고제닉 요통의 생체표지자 식별에 미치는 영향을 강조했습니다.
Nociscan은 MR 분광 신호를 객관적 생체표지자로 전환하여 통증이 있는 요추 디스크와 그렇지 않은 디스크를 구별하고 개인화된 치료 결정을 돕는 SaaS 플랫폼으로 설명됩니다. 이 회사는 다학제 임상 참여와 연구 접근을 위한 영국 클리닉의 보험사 승인에 대해 강조했습니다.
Aclarion (Nasdaq: ACON) a participé à la réunion annuelle de l'International Society of Pain and Neuroscience à Londres le 13 octobre 2025, où une session co‑modérée par Doug Beall, M.D., a mis en lumière le rôle de la MR Spectroscopy et du Nociscan d'Aclarion dans l'identification des biomarqueurs de la douleur lombaire discogénique.
Nociscan est décrit comme une plateforme SaaS qui convertit les signaux de MR spectroscopy en biomarqueurs objectifs afin d'aider à différencier les disques lombaires douloureux des disques non douloureux et d'informer des décisions de traitement personnalisées. L'entreprise a souligné l'engagement clinique multidisciplinaire et l'approbation des assureurs dans une clinique du Royaume‑Uni pour l'accès à l'étude.
Aclarion (Nasdaq: ACON) nahm an der Jahresversammlung der International Society of Pain and Neuroscience in London am 13. Oktober 2025 teil, wo eine von Doug Beall, M.D., co‑moderierte Sitzung die Rolle der MR-Spektroskopie und von Aclarions Nociscan bei der Identifizierung von Biomarkern des dysgener bedingten Rückenschmerzes hervorhob.
Nociscan wird als SaaS-Plattform beschrieben, die MR-Spektroskopiesignale in objektive Biomarker umwandelt, um schmerzhafte vs. schmerzarme Lendenwirbel zu unterscheiden und personalisierte Behandlungsentscheidungen zu informieren. Das Unternehmen betonte das multidisziplinäre klinische Engagement und die Zustimmung der Versicherer in einer Klinik im Vereinigten Königreich für den Studienzugang.
شاركت أكلاريون (ناسداك: ACON) في الاجتماع السنوي للجمعية الدولية للألم وعلوم الأعصاب في لندن في 13 أكتوبر 2025، حيث أبرزت جلسة بإدارة مشتركة مع الدكتور دوغ بيل دور تقنيات MR Spectroscopy و
يُوصف Nociscan بأنه منصة SaaS تحوّل إشارات MR spectroscopy إلى علامات بيولوجية موضوعية للمساعدة في التمييز بين الأقراص القطنية المؤلمة وغير المؤلمة وإبلاغ قرارات العلاج المخصصة. أكدت الشركة على المشاركة السريرية متعددة التخصصات والموافقة من شركات التأمين في عيادة بالمملكة المتحدة للوصول إلى الدراسة.
Aclarion（纳斯达克股票代码：ACON） 在伦敦于 2025年10月13日 参加了国际疼痛与神经科学学会年度会议，其中由Doug Beall博士共同主持的一场会议强调了 MR 波谱与 Aclarion 的 Nociscan 在识别 discogenic 腰痛生物标志物中的作用。
Nociscan 被描述为一个 SaaS 平台，将 MR 波谱信号转化为客观生物标志物，帮助区分疼痛性与非疼痛性腰椎间盘，并为个性化治疗决策提供依据。公司强调了多学科临床参与以及在英国诊所获得的保险公司批准以进入研究。
- None.
- None.
Insights
Aclarion presented Nociscan® MR spectroscopy findings at ISPN, highlighting insurer-backed clinical availability at one UK clinic.
Aclarion presented Nociscan® at the International Society of Pain and Neuroscience meeting in London on
Key dependencies and risks are explicit in the release: broader clinical adoption, third-party payer coverage, and continued inclusion in academic fora. The release notes that one clinic has approval from multiple private medical insurers for a study, which is the only concrete coverage-related fact disclosed. Monitor expansion of insurer approvals, publication of peer-reviewed validation data, and announcements of additional clinical sites over the next 6–18 months.
Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain
Session Co-Moderator Doug Beall, M.D. underscored that disc chemistry is the critical biomarker for diagnosing the leading cause of chronic low back pain
Nociscan® combines MR Spectroscopy and proprietary AI algorithms to deliver data-driven insights that inform treatment decisions to improve patient outcomes
BROOMFIELD, Colo., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced participation in the International Society of Pain and Neuroscience (ISPN) Annual Meeting held last week in London.
Key Highlights:
- Event: International Society of Pain and Neuroscience (ISPN) Annual Meeting — London, UK
- Session Focus: Use and efficacy of MR Spectroscopy in identifying discogenic pain biomarkers
- Company Mission: Establish Nociscan® as the gold standard in identifying sources of chronic low back pain
- Global Relevance: Over 266 million people worldwide suffer from chronic low back pain
Aclarion’s Nociscan® solution is the first evidence-supported SaaS platform to noninvasively help physicians differentiate between painful and non-painful discs in the lumbar spine. Nociscan converts MR spectroscopy signals into objective biomarkers demonstrated to be associated with disc pain. This provides actionable information that enables physicians to develop more personalized treatment plans for patients.
“We are honored to be consistently included in the esteemed academic society meetings, such as ISPN, throughout the spine surgery and pain management ecosystem. This is a testament not only to the innovation of our team today, but to the vision and determination that have guided Aclarion from the very beginning,” said Brent Ness, CEO of Aclarion. “Mr. John Sutcliffe and Dr. Doug Beall represent the forefront of the neurosurgery and interventional radiology community, and we thank them for their moderation of this important discussion.”
“The engaging panel discussion on MR spectroscopy and Nociscan, along with other essential diagnostic modalities for back pain, emphasized that a critical component for diagnosing the most common cause of back pain is the chemistry of the disc,” commented Dr. Beall. “We are very optimistic about the future of MR spectroscopy in diagnosing painful discogenic back pain.”
“The ISPN leadership’s inclusivity of orthopedic and neurosurgeons in the discussions provided an expanded, compelling perspective. We have employed a multidisciplinary spine care approach for over 30 years at the London Spine Clinic, allowing us to pioneer the use of innovative solutions to enhance treatment for our patients,” added John Sutcliffe, co-moderator of the session. “I was honored to co-moderate the important discussion and to share the UK experience with this international audience. We are proud to be the first clinic in the world with the approval from multiple private medical insurers for this study, making it available to an increasing number of appropriate patients.”
To find a Nociscan center, view our site map here.
For more information on Nociscan, please email: info@aclarion.com
About Aclarion, Inc.
Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient’s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit www.aclarion.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company’s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as “anticipates,” “believes” and “expects” or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company’s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the potential benefits of our Nociscan technology, and the Company’s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contacts:
Kirin M. Smith
PCG Advisory, Inc.
ksmith@pcgadvisory.com
Media Contacts:
Jessica Starman
media@elev8newmedia.com
FAQ
What did Aclarion announce at the ISPN Annual Meeting on Oct 13, 2025 regarding Nociscan (ACON)?
How does Nociscan (ACON) claim to help physicians diagnose discogenic low back pain?
Did Aclarion report any clinical approvals or insurer coverage for Nociscan (ACON) at the conference?
What patient population did Aclarion reference for discogenic low back pain (ACON)?
Where can clinicians or patients find a Nociscan center listed by Aclarion (ACON)?
Who co‑moderated the ISPN session that discussed MR Spectroscopy and Nociscan (ACON)?
